ERBB2 and breast cancer: Furthermore, we observed RT patients a lower cumulative incidence of LR than non-RT patients in the luminal A (p < 0.0001), luminal B/HER2-negative (p = 0.02), and luminal B/HER2-positive breast cancer groups (p = 0.005; Fig. 3).